TY - JOUR T1 - Evaluation of glucose-6-phosphate dehydrogenase (G6PD) status in US military and VA patients with COVID-19 infection JF - BMJ Military Health JO - BMJ Mil Health SP - 144 LP - 144 DO - 10.1136/bmjmilitary-2020-001706 VL - 167 IS - 2 AU - Dan J Vick Y1 - 2021/04/01 UR - http://militaryhealth.bmj.com/content/167/2/144.abstract N2 - A recent publication outlined several pieces of evidence suggesting that glucose-6-phosphate dehydrogenase (G6PD) deficiency may increase susceptibility to, and severity of illness with, COVID-19 infection.1 These include an earlier study showing that G6PD-deficient cells are more susceptible to infection in vitro with another coronavirus (HCoV 229E); increased COVID-19 case fatality rates in Spain and Italy, where G6PD deficiency is more common and is typically caused by a variant with more severe manifestations; increased incidence of COVID-19 in Blacks and Asians in the UK and the USA compared with incidence in Caucasians, given that G6PD deficiency is also more common in people of African descent and Asians; similarity in complications of vascular endothelial dysfunction and coagulopathy in some patients with COVID-19 compared with G6PD-deficient individuals under oxidative stress conditions; and case reports of hemolysis in G6PD-deficient patients following initiation of hydroxychloroquine treatment for COVID-19 infection.What is needed at this point are … ER -